
Sunday, June 22, 2025 8:21:52 PM
Highlights
• Magnetotelluric (MT) geophysical survey is well underway; Data from several stations has
already been captured. The survey is on track to finish within the next two weeks.
• Preliminary 1D and 2D resistivity inversions from the first three MT survey lines have been
generated and are under review by the technical team.
• A 3D inversion of the MT data will be completed once all field data is collected, with results
expected 2–4 weeks after survey completion.
• 599 out of the planned 1,200 geochemical samples have been collected (~50% of the
program).
• Approximately 17–20 days remain to complete the geochemical sampling collection
campaign.
Dateline Resources Limited (ASX: DTR, OTCQB: DTREF) (Dateline or the Company) is pleased to
provide an update on exploration activities at its 100%-owned Colosseum Gold-REE Project in San
Bernardino County, California.
The magnetotelluric (MT) survey is progressing on schedule. The geophysics contractor has collected
data from 119 out of 167 stations and the survey is approximately 70% complete. The MT survey is
designed to collect deep subsurface resistivity data along multiple lines spanning the claims,
imaging geological structures and alteration zones that could indicate buried breccia pipes or other
REE bearing mineralized features. These data, together with results from the recent gravity survey
and pending geochemical assays, will collectively inform the Company’s drill targeting strategy
under its “stacked evidence” exploration approach.
Importantly, preliminary MT results are already emerging. The first three survey lines have been
completed, and preliminary 2D resistivity cross-sections have been generated from this data. These
initial images are currently being reviewed by Dateline’s technical team and show resistivity
contrasts that may correlate with key lithological contacts or structural features at depth.
Glidelogic Corp. Announces Release of First AI-Generated Novel "The Thirteenth Proposal" • GDLG • Jul 11, 2025 12:20 PM
Fifty1 AI Labs' REVIVE Clinical Trial Redefines Long COVID Treatment, Pioneering AI-Driven Therapies and Propelling Fifty 1 Labs, Inc. Toward $50M Valuation and Global Biotech Leadership • FITY • Jul 10, 2025 8:30 AM
Aspire Biopharma Holdings, Inc., Announces Positive Consumer Feedback from Company Sampling of BUZZ BOMB™, its New Sublingual Pre-Workout Supplement • ASBP • Jul 9, 2025 9:15 AM
Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers • IBRX • Jul 9, 2025 9:00 AM
Fifty 1 Labs, Inc. Announces Bold Expansion Plan Powered by Nobel Prize Laureate Management Team, Cutting-Edge AI Healthcare Innovation and $350K Leadership Investment • FITY • Jul 8, 2025 8:30 AM
Avant Technologies and Partner, Ainnova, Launch Transformative Preventative Care Model for Chronic Patients Across Latin America • AVAI • Jul 8, 2025 8:00 AM